This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
The study objective is to clinically validate that the presence of recently discovered novel genetic variation adversely affects a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients using biobank samples.
Study Type
OBSERVATIONAL
Enrollment
80
Stanford University
Stanford, California, United States
Novel genetic variants impact on 6-mercaptopurine adverse drug reactions
Objective is to clinically validate the presence of novel genetic variants and its impact on adverse drug reactions in a population of pediatric ALL patients treated with 6-MP
Time frame: 1 year
Evaluating relationship of genetic variants to ancestry
A secondary objective of this study is to compare the impact of the novel genetic variants with other known genetic variants contributing to ADR risk.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.